Indications

 

NT 101: Severe Radiation Dermatitis (Radiation Burns)

Studies indicate that within 7 - 14 days of initiating radiation treatment, 90% of cancer patients develop some degree of redness, blistering and even ulceration of the skin. In 10% of these cases severe “burns” develop causing interruption or delay of radiotherapy. The problem is particularly significant in breast, and head and neck cancer patients where the tumor lies close to the skin and the skin dose of radiotherapy is relatively high. Current therapies primarily use soothing lotions which only have a minimal effect in severe cases and do not cure the underlying skin damage. NellOne studies have shown the potential to accelerate the recovery of irradiated skin.

NT 201: Major Trauma

According to the NHDS there are about 80,000 major trauma patients hospitalized each year in the US, the majority of whom will suffer damage to, or loss of, skeletal muscle. Current approaches (e.g. scaffolds and matrices with or without cells and/or bioactive factors) have not demonstrated the ability to regenerate functional muscle in a large wound. For most patients, building new muscle is a slow process brought on by physical therapy, which is often inefficient because of limited mobility and persistent pain. NellOne studies suggest the potential to accelerate the regeneration of skeletal muscle after major trauma.

NT 301: Cardiac Muscle Regeneration

There are more than 800,000 heart attack cases each year in the US alone. Many companies are pursuing cell implantation approaches, which face challenges such optimal cell type choice, poor cell engraftment at the treatment site, adverse immunologic responses and cell storage difficulties. Others are developing growth factor type therapies, which may lead to the accumulation of new cell mass, but fail to orchestrate cellular organization into functional contractile tissue. NellOne research suggests that NELL1 maintains an active re-growth and remodeling environment via the ECM enabling true regeneration of cardiac muscle tissue after heart attack.

These investigational drug products have not been approved by the US Food and Drug Administration.